The latest at the Foundation | Access to Medicine Foundation

MPP Strategy Launch Event: Jayasree K. Iyer to speak on the expansion of novel medical technologies

30 January 2023

Foundation names Expert Committee for the Generic Medicine Manufacturers Research Programme

25 November 2022

Investor Action on Antimicrobial Resistance progress report

21 November 2022

Drugmakers that dominate the world's insulin market must scale up access efforts globally

06 October 2022

Index finds more pharma companies moving to address access to medicine. Will they now go further?

15 November 2022

Resource Center

Read the best practices and findings from 2022 Access to Medicine Index

Featured Key findings

Some companies engaging in R&D for emerging infectious diseases, but pipeline mainly empty

15 November 2022

First voluntary licence for a cancer treatment is a promising sign for future expansion of access to innovative medicines

15 November 2022

Featured Key findings

More access plans and strategies to expand access to more products, but with limited breadth and depth

15 November 2022

Implementing strong access strategies across different country income classifications

15 November 2022

GSK in top spot, Johnson & Johnson close second. AstraZeneca leaps up to join the top three. Bayer and Merck climb the Index ranking.

Drug makers must address access to antibiotics to help slow the superbug threat

International Conference on Public Health in Africa: Building more resilient health systems

13 December 2022

Are pharma companies addressing sexual and reproductive health access barriers for women and girls?

18 November 2022

Achievements so far

Read more about the Foundation's impact

Closing the gaps in access to diabetes care in low- and middle-income countries

Global oxygen suppliers commit to closing oxygen gaps in low- and middle-income countries